Functional evidence for the ability of angiotensin AT1 receptor antagonists to cross the blood-brain barrier in rats
References (42)
- et al.
Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier
Eur. J. Pharmacol.
(1992) - et al.
Drinking induced by subcutaneous injection of angiotensin II in the rat is blocked by the selective AT1 receptor antagonist Dup753, but not by the selective AT2 receptor antagonist WL19
Eur. J. Pharmacol.
(1992) - et al.
Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat
Brain Res. Bull.
(1993) - et al.
Comparison of c-fos expression in the Lamina Terminalis of conscious rats after intravenous or intracerebroventricular angiotensin
Brain Res. Bull.
(1995) - et al.
Drinking induced by central injection of angiotensin II in the rat is blocked by the new selective At1 antagonist LR-B/081
Eur. J. Pharmacol.
(1995) - et al.
Molecular pharmacology of LR-B/081, a new non-peptide AT1 receptor antagonist
Eur. J. Pharmacol.
(1995) - et al.
Effect of nonpeptide angiotensin receptor antagonists on water intake and salt appetite in rats
Brain Res. Bull.
(1992) - et al.
Role of angiotensin II and AT1 receptors in hippocampal LTP
Pharmacol. Biochem. Behav.
(1993) - et al.
Regulatory role of brain angiotensins in the control of physiopatological and behavioral responses
Brain Res. Rev.
(1992) - et al.
Anxiolytic-like action of DuP753, a non-peptide angiotensin II receptor antagonist
NeuroReport
(1990)
Intracerebroventricular angiotensin II-induced thirst and sodium appetite in rats are blocked by the AT1 receptor antagonist, losartan (DuP 753), but not by the AT2 antagonist, CGP 42112B
Exp. Physiol.
Angiotensin II receptor blocking Imidazoles
Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist
Br. J. Pharmacol.
Differential effects of the AT1 receptor antagonists GR117289 and GR 138950 on AT1 receptor-mediated dipsogenic responses and in a brain ex vivo binding assay in the rat
Br. J. Pharmacol.
Hypertension and the Angiotensin System: Therapeutic Approaches
Prospectus: thirst and salt appetite
The Physiology of Thirst and Sodium Appetite
Endogenous angiotensin and sodium appetite
Effect of a non peptide angiotensin II receptor antagonist, Dup753, on angiotensin-related water intake in rats
Brain Res. Bull.
Impaired drinking responses of rats with lesions of the nucleus medianus: circadian dependence
Am. J. Physiol.
Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist
Br. J. Pharmacol.
Cited by (55)
Brain-targeted delivery of losartan through functionalized liposomal nanoparticles for management of neurogenic hypertension
2023, International Journal of PharmaceuticsThe contribution of angiotensin peptides to cardiovascular neuroregulation in health and disease
2023, Angiotensin: From the Kidney to CoronavirusPreliminary study of ovariectomy and chronic losartan-induced alterations in brain AT<inf>1</inf> receptors
2021, Brain ResearchCitation Excerpt :Previously, we showed that the ARB, losartan prevents anxiety-like behavior and cognitive impairments induced by ovariectomy in a normotensive Long-Evans rats (Campos et al., 2019). To explore this relationship, we assessed changes in brain AT1 receptor binding in 5 brain regions as a function of ovariectomy and treatment with the ARB losartan, which has been shown to cross the blood–brain-barrier to inhibit AT1R binding and activation (Song et al., 1991; Li et al., 1993; Polidori et al., 1996) when administered peripherally. There was a significant difference in brain AT1R binding between brain regions, but no significant difference between males and females except for a trend toward increased AT1R expression in the intact male amygdala compared to the sham-vehicle female.
Angiotensinergic neurotransmission in the paraventricular nucleus of the hypothalamus modulates the pressor response to acute restraint stress in rats
2014, NeuroscienceCitation Excerpt :The dose of losartan presently used was chosen considering previous reports in the literature (Kauffman et al., 1991; Levine et al., 1996; Wang et al., 1997), including a pharmacokinetic study on losartan (Moon et al., 1998). Concerning action on the CNS, there is evidence in the literature indicating that AT1-antagonists cross the blood–brain barrier and act in the CNS (Li et al., 1993; Polidori et al., 1996; Nishimura et al., 2000), and that losartan central effects would last longer than restraining session duration (>60 min). The antagonism produced by a 3-mg/kg i.v. dose of losartan on the local neuronal activation resulting from AngII microinjection into the PVN has been reported to last for 75 min (Li et al., 1993), whereas that observed after the i.p. administration of a 10-mg/kg dose of losartan on rat water intake remained for 24 h (Polidori et al., 1996).
Angiotensin-(1-7)/Mas axis integrity is required for the expression of object recognition memory
2012, Neurobiology of Learning and MemoryCitation Excerpt :Losartan (Sigma–Aldrich) 10 mg/kg was administered by intraperitoneal (i.p.) injection, 18 h and 1 h prior training (Raghavendra, Chopra, & Kulkarni, 2001). It is well accepted that this dose of losartan crosses the brain blood barrier and functionally blocks their targets in the brain (Polidori, Ciccocioppo, Pompei, Cirillo, & Massi, 1996; Tota et al., 2009; Wang, Tan, & Leenen, 2003). PD123319 (Sigma–Aldrich) 1 mg/kg was administered by subcutaneous (s.c.) injection, 12 h and 1 h before training session (Macova, Pavel, & Saavedra, 2009).
- 1
Present address: Menarini Ricerche Sud, Via Tito Speri 10, 00040 Pomezia, Rome, Italy.